First Citizens BancShares, Inc. (FCNCA)

First Citizens BancShares is trading near the top of its yearly range, with the stock up 27.42% over the past year and 11.81% above its 200-day average. The move has come even though the shares fell after seven of the last eight earnings reports, including the first session after each of the last three, despite every report beating the analysts' EPS estimate. The price sits 4.71% below its 52-week high of $2,429.96, so the next test is whether the stock can clear that ceiling or whether it pulls back toward its moving averages. Analysts remain cautious, with a Hold consensus and a median 12-month target of $2,500.00.

Every one of the last eight reports beat the analysts' EPS estimate, and the beats ranged from 14.35% to 42.16%. The October 23, 2026 report showed adjusted EPS of $55.37 against an estimate of $45.98, a beat of 20.42%. Even so, the share price fell in the first session after that report, down 1.27%. The pattern repeats across the record: seven of the eight reports were followed by a lower price in the first session, and the only rise came after one report. The company's earnings are clearly ahead of forecasts, but the market has not paid up for that surprise on the day it arrives.

At a trailing P/E of 11.80, the stock trades 28.5% below the sector median P/E of 16.5, which the Peer Benchmarking card classes as a discount to peers. The price-to-sales ratio of 2.70 is 28.9% below the sector median of 3.8. Return on equity of 10.98% is below the sector median of 13.8%, though the net profit margin of 24.1% and operating margin of 37.26% are solid. The discount reflects slower growth and lower returns rather than weak earnings.

Of 13 analysts with a current rating, two rate the stock buy or strong buy, ten rate it hold and one rates it sell or strong sell. Three months earlier there were two buy ratings out of 12. The most recent move was JP Morgan's downgrade to Underweight from Neutral on October 26, 2026, while Truist Securities kept its Hold rating on October 28, 2026. The median 12-month target of $2,500.00 is 8.0% above the price, and the range runs from $2,200.00 to $2,730.00.

Over the last 18 months, insiders sold $15.4M of stock across two sales and bought $160K across four open-market purchases. Insider sales are often planned in advance or made to cover tax on vesting shares, so the sales carry less signal than the purchases, which were small by comparison.

The base case is that the stock keeps its uptrend while it holds above its 50-day and 200-day moving averages ($2,173.29 and $2,071.06) and earnings keep beating estimates. The analysts' average EPS estimate for this year is $205.50, expected to grow 15.5%, and for next year $216.15, growth of 5.2%, so the earnings path is steady rather than fast. Revenue is expected to grow only 1.4% this year, which limits how much the earnings beats can lift the stock. The upside case rests on a clean break above the 52-week high of $2,429.96 and a move toward the median target of $2,500.00 or the highest target of $2,730.00. The downside case is a fall through the 20-day EMA and the 50-day SMA, which would bring the 200-day SMA of $2,071.06 into view. Ratings are mixed: two buy ratings, ten holds and one sell, and JP Morgan's October 26 downgrade to Underweight adds to the caution. A simulation from past volatility is not a forecast, but the stock's 1.85% typical daily move gives a sense of the scale of swings to expect.

Support sits first at the 20-day EMA of $2,270.83, the nearest level below the price. Below it, the 50-day SMA of $2,173.29 is the next support, followed by the 200-day SMA of $2,071.06. The 52-week low of $1,759.27 is the deepest level below the price. Resistance is the 52-week high of $2,429.96, the nearest level above the price and the first level a rise would meet. The analysts' median target of $2,500.00 sits above that high and marks the next level analysts point to.